<DOC>
	<DOCNO>NCT00635219</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability three fix dos Vortioxetine order establish appropriate clinical effective dose range treatment Major Depressive Disorder ( MDD ) .</brief_summary>
	<brief_title>Randomised Placebo-controlled Duloxetine-referenced Efficacy Safety Study 2.5 , 5 10 mg Vortioxetine ( Lu AA21004 ) Acute Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>MDE primary diagnosis accord DSMIVTR criterion ( classification code 296.xx ) Moderate severe depression Current MDE duration least 3 month Any current psychiatric disorder MDD define DSMIV TR Any substance disorder within previous 6 month Female patient childbearing potential use effective contraception Use psychoactive medication 2 week prior screen study Other protocoldefined inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Active reference</keyword>
	<keyword>Multicenter study</keyword>
	<keyword>Randomised study</keyword>
	<keyword>Acute treatment</keyword>
</DOC>